News
Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.
ANSM: Point de situation sur la surveillance des vaccins contre la COVID-19
Dans le cadre de la surveillance renforcée des vaccins utilisés contre la Covid-19, une enquête de pharmacovigilance est mise en place pour surveiller en temps réel le profil de sécurité des vaccins à partir des [...]
ANSM: Médicaments antalgiques contenant du tramadol par voie orale (seul ou en association) – Limitation de la durée maximale de prescription à 12 semaines
Information destinée aux médecins généralistes, médecins spécialistes, libéraux et hospitaliers, dontles médecins des hôpitaux et cliniques publics et privés, les médecins urgentistes et les médecinsexerçant en EHPAD, chirurgiens-dentistes, sages-femmes, pharmaciens d’officine et hospitaliers(PUI) Nous souhaitons [...]
(Cas) AEMPS: Boletín mensual de seguridad de la AEMPS sobre medicamentos de uso humano del mes de noviembre de 2020
Sorry, this entry is only available in European Spanish. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.Recoge nuevos [...]
EMA: Human medicines: highlights of 2020
EMA has published an overview of its key recommendations in 2020 on the authorisation and safety monitoring of medicines for human use. In 2020, EMA recommended 97 medicines for marketing authorisation. Of these, 39 had a new active substance which [...]
FDA Approves First Extended-Release, Injectable Drug Regimen for Adults Living with HIV
The U.S. Food and Drug Administration today approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace a current [...]
EMA: Global regulators highlight key role of healthcare professionals in fostering confidence in COVID-19 vaccines
EMA has endorsed a joint statement published today by the International Coalition of Medicines Regulatory Authorities (ICMRA) to inform and help healthcare professionals answer questions about the evaluation, approval and monitoring of safe, effective and high-quality COVID-19 [...]